Us Acromegaly Drugs Market
Marktgröße in Milliarden USD
CAGR :
% 
 Prognosezeitraum |
2024 –2031 |
 Marktgröße (Basisjahr) | USD 759.71 Million |
 Marktgröße (Prognosejahr) | USD 1,247.90 Million |
 CAGR |
% |
| Wichtige Marktteilnehmer |
U.S. Acromegaly Drugs Market Segmentation, By Disease Type, (Pseudo acromegaly, Ectopic Acromegaly), Drug Class, (Somatostatin Analogues, Growth Hormone Receptor Antagonists, Dopamine Agonists), Drugs Type (Branded Generic), Route of Administration (Parenteral, Oral), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy) - Industry Trends and Forecast to 2031.
U.S. Acromegaly Drugs Market Size
U.S. acromegaly drugs market size was valued at USD 759.71 million in 2023 and is projected to reach USD 1247.90 million by 2031, with a CAGR of 6.4% during the forecast period of 2024 to 2031.
Report Scope and Market Segmentation
|
Attributes |
Acromegaly Drugs Key Market Insights |
|
Segmentation |
By Disease Type: Pseudo acromegaly, Ectopic Acromegaly By Drug Class: Somatostatin Analogues, Growth Hormone Receptor Antagonists, Dopamine Agonists By Drugs Type: Branded Generic By Route of Administration: Parenteral, Oral By End User: Hospitals, Specialty Clinics, Homecare, Others By Distribution Channel: Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy |
|
Countries Covered |
U.S. |
|
Key Market Players |
Novartis AG, Mylan N.V., Ipsen Pharma, Pfizer Inc., Fresenius Kabi USA (A Subsidiary of Fresenius Kabi AG), Zydus Pharmaceuticals Inc. (A Subsidiary of Zydus Cadila), Par Pharmaceuticals (A Subsidiary of Endo International plc), Hikma Pharmaceuticals PLC, Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.), Chiasma, Inc., Ingenus Pharmaceuticals, LLC, Recordati Rare Diseases (a subsidiary of RECORDATI S.p.A.), Sun Pharmaceutical Industries Ltd. and Sagent Pharmaceuticals, Inc. (A Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd.) |
U.S. Acromegaly Drugs Market Dynamics
The U.S. acromegaly drugs market is growing primarily due to increasing focus on the high prevalence of the acromegaly. The availability of wide variety of treatments and presence of several companies focusing on development of acromegaly drugs is also acting as significant growth factors for the market.
Acromegaly drugs market comprises features such as strategic initiatives by market players will impact in launching new product by the manufactures into the market which enhance its demand as well as technological advancements has enhanced the demand of acromegaly drugs. Currently various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative and advanced acromegaly drugs which expected to provide various other opportunities in the acromegaly drugs market. However, the lack of early detection and complication associated with treatment expected to restraint the market growth in the forecast period. The treatment of acromegaly includes multiple types of therapies with advance drug such as somatostatin analogs (SSAs), growth hormone receptor antagonists (GHRAs) and dopamine agonists. However the treatment of acromegaly is very expensive which is hampering the demand of the market. Growing number of dentistry anticipated to escalate the diagnosis of acromegaly disease. Consequently it is estimated that the U.S. acromegaly drugs market will rise up in the coming years.
The acromegaly drugs market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
U.S. Acromegaly Drugs Market Scope
Acromegaly drugs market is segmented on the basis of disease type, drugs class, drugs type, route of administration, end user and distribution channel. The growth among segments helps you to analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Disease Type
- Ectopic Acromegaly
- Pseudo Acromegaly
Drugs Class
- Somatostatin Analogue
- Growth Hormone Receptor Antagonists
- Dopamine Agonists
Drugs Type
- Branded
- Generics
Route of Administration
- Parenteral
- Oral
End User
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospitals Pharmacy
- Retail Pharmacy
- Online Pharmacy
Acromegaly Drugs Market Share Analysis
U.S. acromegaly drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to U.S. acromegaly drugs market.
Acromegaly Drugs Market Leaders Operating in the Market Are:
- Novartis AG, Mylan N.V.
- Ipsen Pharma
- Pfizer Inc.
- Fresenius Kabi USA (A Subsidiary of Fresenius Kabi AG)
- Zydus Pharmaceuticals Inc. (A Subsidiary of Zydus Cadila)
- Par Pharmaceuticals (A Subsidiary of Endo International plc)
- Hikma Pharmaceuticals PLC
- Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)
- Chiasma, Inc.
- Ingenus Pharmaceuticals, LLC
- Recordati Rare Diseases (a subsidiary of RECORDATI S.p.A.)
- Sun Pharmaceutical Industries Ltd.
- Sagent Pharmaceuticals, Inc. (A Subsidiary of Nichi-Iko Pharmaceutical Co., Ltd.)
Latest Developments in Acromegaly Drugs Market
- In January 2020, Novartis AG announced the acquisition of the Medicines Company through the consummation of a merger of its indirect wholly-owned subsidiary, Medusa Merger Corporation. This acquisition has provided unique opportunity to expand the presence of Novartis AG’s products across the world.
- In November 2019, Novartis AG acquired The Medicines Company to acquire the U.S. based biopharmaceutical company. This acquisition has been estimated to raise the company presence in the U.S. market. Consequently, it will propel the revenue growth of the company.
Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the U.S. acromegaly drugs market which also provides the benefit for organization to improve their offering for acromegaly drugs.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
